Ixazomib Plus Lenalidomide-Dexamethasone (IRd) in Relapsed/Refractory Multiple Myeloma (MM) Patients (Pts) - Effectiveness in Routine Clinical Practice Is Similar to the Efficacy in the Phase 3 Tourmaline-MM1 Trial: A Pooled Analysis from the Insight MM Observational Study and the Czech Registry of Monoclonal Gammopathies (RMG)
Year: 2018
Type: conference-abstract
Source: Blood
Authors: Roman Hajek, Evangelos Terpos, Hans C. Lee, Ajai Chari, Caitlin L. Costello, Noemi Puig, Xavier Leleu, Jesus G. Berdeja, Faith E. Davies, Katja Weisel, Saad Z. Usmani, Vania T. M. Hungria, Mario Boccadoro, Robert M Rifkin, Jeffrey A Zonder, Gordon Cook, Lucie Brožová, Magda Bařinová, Kaili Ren, Roxanne Cacioppo, Tomas Skacel, Dawn Marie Stull, Vladimir Maisnar
Institutions: University Hospital Ostrava, National and Kapodistrian University of Athens, The University of Texas MD Anderson Cancer Center, Icahn School of Medicine at Mount Sinai, University of California San Diego, Moores Cancer Center, Complejo Hospitalario de Salamanca, Centre Hospitalier Universitaire de Poitiers, Sarah Cannon, University of Arkansas Medical Center, University of Arkansas for Medical Sciences, Universitätsklinikum Tübingen, Levine Cancer Institute, São Germano Oncologia, University of Turin, Rocky Mountain Cancer Centers, Wayne State University, The Barbara Ann Karmanos Cancer Institute, Leeds Teaching Hospitals NHS Trust, National Institute for Health and Care Research, Takeda Oncology (United States), Charles University
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2898760573